FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1850871037> ?p ?o ?g. }

• W1850871037 abstract "HomeHypertensionVol. 37, No. 5Trends in Antihypertensive Drug Therapy by US Office-Based Physicians Free AccessOtherPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessOtherPDF/EPUBTrends in Antihypertensive Drug Therapy by US Office-Based Physicians E. Andrew Balas E. Andrew BalasE. Andrew Balas Center for Health Care Quality, University of Missouri-Columbia, Columbia, Missouri Search for more papers by this author Originally published1 May 2001https://doi.org/10.1161/01.HYP.37.5.e12Hypertension. 2001;37:e12To the Editor:We read with great interest the article by Nelson and Knapp1 on the trends of antihypertensive therapy by US office-based physicians. Their findings are clearly significant, but some of their conclusions are not supported by the data presented. The authors state that “physician antihypertensive drug prescribing was generally consistent with the basic antihypertensive drug guidelines of the JNC reports.” However, they also note that calcium channel blocker visits increased from 1.9% in 1985 to 39.8% in 1995 and that ACE inhibitor/receptor blocker visits increased from 6.4% to 37.0%, while all other drug classes decreased, including the JNC’s preferred step 1 agents of β-adrenergic blockers and diuretics. Moreover, while in 1995 monotherapy with either calcium channel blockers or ACE inhibitors together made up 39.5%, monotherapy with the JNC V’s preferred step 1 monotherapy of either diuretics or β-adrenergic blockers accounted for only 19.6% of antihypertensive drug visits.1 This is much more in accordance with the findings of previous studies in the United States2 and Europe,34 which found no effect of prescription guidelines on antihypertensive therapy by physicians. The profound increase in newer, expansive, patented products such as calcium channel blockers, ACE inhibitors, and angiotensin receptor blockers seen in this and other studies has been attributed to the effect of intense promotion by drug manufacturers.35 One can only wonder why doctors do not follow recommendations by their professional organizations but rather the promotion campaigns of pharmaceutical companies, and what could be done to change this unfavorable situation. References 1 Nelson CR, Knapp DA. Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension.2000; 36:600–603.CrossrefMedlineGoogle Scholar2 Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 997;278:1745–1748.Google Scholar3 Szekacs B, Vajo Z, Szepezdi Z. Diuretics for hypertension JAMA..1999; 282:524.Google Scholar4 Jabary NS, Herrero AM, Gonzalez JA. The use of antihypertensive therapy in Spain (1986–1994). Am J Hypertens.2000; 13:607–610.CrossrefMedlineGoogle Scholar5 Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA.1998; 279:1813–1816.CrossrefMedlineGoogle ScholarhypertensionahaHypertensionHypertensionHypertension0194-911X1524-4563Lippincott Williams & WilkinsResponseNelson Cheryl R. and Knapp Dee A.052001Clearly, what is needed to address your concerns is a better explanation of what we meant by “basic antihypertensive drug guidelines of the JNC reports.” What we meant as “basic” is any of the “initial” step 1 antihypertensive drug classes as given in JNC V (Table 7) and JNC VI (Figure 8) (see our article for references). eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetails May 2001Vol 37, Issue 5 Advertisement Article InformationMetrics https://doi.org/10.1161/01.HYP.37.5.e12 Originally publishedMay 1, 2001 PDF download Advertisement" @default.
• W1850871037 created "2016-06-24" @default.
• W1850871037 creator A5042604865 @default.
• W1850871037 date "2001-05-01" @default.
• W1850871037 modified "2023-10-14" @default.
• W1850871037 title "Trends in Antihypertensive Drug Therapy by US Office-Based Physicians" @default.
• W1850871037 cites W1968125938 @default.
• W1850871037 cites W1991507588 @default.
• W1850871037 cites W2016889447 @default.
• W1850871037 doi "https://doi.org/10.1161/01.hyp.37.5.e12" @default.
• W1850871037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11358954" @default.
• W1850871037 hasPublicationYear "2001" @default.
• W1850871037 type Work @default.
• W1850871037 sameAs 1850871037 @default.
• W1850871037 citedByCount "2" @default.
• W1850871037 crossrefType "journal-article" @default.
• W1850871037 hasAuthorship W1850871037A5042604865 @default.
• W1850871037 hasBestOaLocation W18508710371 @default.
• W1850871037 hasConcept C126322002 @default.
• W1850871037 hasConcept C27016395 @default.
• W1850871037 hasConcept C2776999253 @default.
• W1850871037 hasConcept C2779611605 @default.
• W1850871037 hasConcept C2780035454 @default.
• W1850871037 hasConcept C2780192228 @default.
• W1850871037 hasConcept C2780356492 @default.
• W1850871037 hasConcept C500440147 @default.
• W1850871037 hasConcept C71924100 @default.
• W1850871037 hasConcept C84393581 @default.
• W1850871037 hasConcept C98274493 @default.
• W1850871037 hasConceptScore W1850871037C126322002 @default.
• W1850871037 hasConceptScore W1850871037C27016395 @default.
• W1850871037 hasConceptScore W1850871037C2776999253 @default.
• W1850871037 hasConceptScore W1850871037C2779611605 @default.
• W1850871037 hasConceptScore W1850871037C2780035454 @default.
• W1850871037 hasConceptScore W1850871037C2780192228 @default.
• W1850871037 hasConceptScore W1850871037C2780356492 @default.
• W1850871037 hasConceptScore W1850871037C500440147 @default.
• W1850871037 hasConceptScore W1850871037C71924100 @default.
• W1850871037 hasConceptScore W1850871037C84393581 @default.
• W1850871037 hasConceptScore W1850871037C98274493 @default.
• W1850871037 hasIssue "5" @default.
• W1850871037 hasLocation W18508710371 @default.
• W1850871037 hasLocation W18508710372 @default.
• W1850871037 hasOpenAccess W1850871037 @default.
• W1850871037 hasPrimaryLocation W18508710371 @default.
• W1850871037 hasRelatedWork W143040108 @default.
• W1850871037 hasRelatedWork W2004283873 @default.
• W1850871037 hasRelatedWork W2015008105 @default.
• W1850871037 hasRelatedWork W2021486511 @default.
• W1850871037 hasRelatedWork W2072663470 @default.
• W1850871037 hasRelatedWork W2364520870 @default.
• W1850871037 hasRelatedWork W2395552301 @default.
• W1850871037 hasRelatedWork W2588063901 @default.
• W1850871037 hasRelatedWork W3154729767 @default.
• W1850871037 hasRelatedWork W4316466636 @default.
• W1850871037 hasVolume "37" @default.
• W1850871037 isParatext "false" @default.
• W1850871037 isRetracted "false" @default.
• W1850871037 magId "1850871037" @default.
• W1850871037 workType "article" @default.